SCAI Statement on Thyroid Monitoring in Young Children Receiving Iodinated Contrast Media
SCAI believes that the current data is insufficient to warrant the course of action described within the recent Food and Drug Administration Drug Safety Communication and that further studies are needed to define at-risk groups accurately, clarify the risks of ICM exposure, and provide rational monitoring and treatment guidelines.
Mar 7th, 2022
Article
Mar 1st, 2022
Article
Feb 25th, 2022
Article
Feb 15th, 2022
Article
Feb 15th, 2022
Article
Feb 14th, 2022
Article
Top 10 SCAI Government Relations Successes in 2021
Learn more about SCAI's advocacy efforts on the issues that our important to our community and its patients.
Feb 1st, 2022
Article
Jan 31st, 2022
Article
SCAI Releases Updated Expert Consensus to SCAI SHOCK Classification
Update includes modifications and clarifications based on accrued data and experience with the classification scheme.
Jan 27th, 2022